Precision oncology company Guardant Health Inc (Nasdaq:GH) said on Thursday that it has entered a multi-year global collaboration with biopharmaceutical company Pfizer Inc (NYSE:PFE) to support the development and commercialisation of Pfizer's oncology portfolio using Guardant's Infinity smart liquid biopsy platform.

The partnership will integrate Guardant's portfolio of liquid biopsy tests into Pfizer's clinical studies and research initiatives. A key focus is evaluating the use of circulating tumour DNA as a surrogate endpoint for monitoring therapy response, along with related blood-based epigenomic analyses.

As part of the agreement, Pfizer will also gain access to Guardant's liquid biopsy tests in China to support clinical trials involving Chinese patient cohorts. This access builds on Guardant's existing partnership with Adicon Holdings Limited, announced in July 2022, to expand availability of its tests in China.

The collaboration underscores both companies' commitment to advancing precision oncology through non-invasive diagnostic technologies.